Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex (NCT03715478)
A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination With Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and low-dose PO dexamethasone in subjects with relapsed and/or refractory MM.
Who can join: Review the eligibility criteria below.
Location: Cross Cancer Institute — Edmonton, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Cross Cancer Institute — Edmonton, Alberta
- Vancouver General Hospital — Vancouver, British Columbia
- CancerCare Manitoba — Winnipeg, Manitoba
- QEII Health Sciences Centre — Halifax, Nova Scotia
- Juravinski Cancer Centre — Hamilton, Ontario
- London Health Sciences Centre — London, Ontario
- The Ottawa Hospital — Ottawa, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- Allan Blair Cancer Centre — Regina, Saskatchewan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed and/or Refractory Multiple Myeloma
Explore by condition: All Relapsed and/or Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.